

REMARKS

In response to the previous Official Action, applicants hereby amend their application to make clear that their device is a spring driven drug delivery device that incorporates a dial up and dial down means. US 5,104,380 discloses a dial-up spring-actuated pen in which dose setting is accomplished by a one-way ratchet mechanism being in constant engagement, the mechanism allowing energy to build up in a spring until it is released. It is impossible to reduce the size of a set dose with the device disclosed in the '380 patent without expelling some of the dose, i.e, it has no dial-down feature.

US 5,626,566 discloses a dial-up user-actuated pen in which dose setting is accomplished by a one-way ratchet mechanism being in constant engagement under normal use circumstances, however, it is possible to disengage the ratchet mechanism by pulling two components of the dosing mechanism apart, thereby allowing the user to dial-down the set dose.

Thus, the prior art cited by the Examiner when taken in combination shows a spring drive pen and a non-spring driven pen syringe. The non-spring driven pen syringe, of which a sample was left with the Examiner during a previous interview with Applicants' attorney, allows a dose to be reduced only after disengagement of a two components within the dosing mechanism. Thus, the two references when considered in combination do not show the claimed invention which requires that the pen have a mechanism for allowing a user to dial up a dose and then reduce the dose by dialing it down without disengaging various parts within the dose setting mechanism. Applicants' have invented a spring driven pen syringe that allows a dose to be set and then adjusted downward by merely reversing the operation of setting the dose. This feature is

Attorney Docket No.: 6166.200-US
Express Mail Label No: EV 409530770 US
not suggested by the combined cited.

In view of the above, applicants respectfully submit that all claims are
in condition for allowance.

Attorney Docket No.: 6166.200-US
Express Mail Label No: EV 409530770 US

The Commissioner is hereby authorized to charge any fees, including fees for extensions of time, in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. Should the Examiner have any questions or concerns, she should feel free to contact the applicants' attorney to discuss them.

Date: May 21, 2004

Respectfully submitted,



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

**Use the following customer number for all correspondence
regarding this application**

23650
PATENT TRADEMARK OFFICE